Navigation Links
Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
Date:12/3/2008

WORCESTER, Mass. Dec. 3, 2008 Interleukin-12 is a naturally occurring protein essential for the proper functioning of the human immune system. Having either too much or too little interleukin-12 may play a role in the development of many diseases, including some cancers and auto-immune disorders like Crohn's, psoriasis, and rheumatoid arthritis. In turn, modulating interleukin-12 levels could yield new therapies for those conditions.

In an effort to create a new and cost-effective method for producing interleukin-12 and make more of the scarce protein available for research and therapeutic development, a team of scientists at Worcester Polytechnic Institute's Life Sciences and Bioengineering Center (WPI) and the Arkansas Bioscience Institute at Arkansas State University (ABI) reports that hairy roots from genetically modified tobacco plants can be grown in a contained novel mist bioreactor system, yielding significant quantities of murine interleukin-12. A paper detailing the results of the study has been published early, online, by the journal Biotechnology and Bioengineering and will appear in the journal's printed edition early in 2009.

"We are very encouraged by the results of this study," says Pamela J. Weathers, PhD, professor of biology and biotechnology at WPI, co-author of the paper. "Interluekin-12 is a valuable protein and there just isn't enough available for biomedical research, let alone for therapeutic development. Our study shows that we can use plants to produce interleukin-12, and other therapeutic proteins, in a cost-effective controlled process."

The tobacco project is one of several emerging collaborative efforts between WPI and ABI. In the current study, tobacco plants were modified in the lab of Carole Cramer, PhD, ABI's executive director and co-author of the paper. Cramer's team successfully inserted into tobacco plants a mouse gene that directs the production of interleukin 12. Hairy root cultures fr
'/>"/>

Contact: Michael Cohen
mcohen@wpi.edu
508-868-4778
Worcester Polytechnic Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
2. USC researchers identify novel approach for suppressing prostate cancer development
3. Studies show novel device may enhance chemotherapy treatment in brain tumors
4. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
5. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
6. E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd
7. Novel imaging technique reveals brain abnormalities that may play key role in ADHD
8. Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue
9. Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial
10. Novel 4-drug combination proves safe for lung cancer treatment
11. Porter Novelli Named Agency of Record for Pharmavite(R) LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/9/2009)...-- , - New Online Service Provides the Best... Whatever Age , A new website has been laun...ned specifically to get rid of all examination, te...and it can be found at, http://www.befreefrom.com...ction, there and then, on how to get rid of exam a...
(Date:1/8/2009)...re/ -- The Alliance for the Prudent Use of Antibio...paigns by Wal-Mart, Stop and Shop, Publix, and oth...otics to customers. These offers are portrayed as ...ed costs in the form of treatment failures because...d for affordable healthcare is indisputable, provi...
(Date:1/8/2009)...-USNewswire/ -- Today, the National Hospice and Pa...onal leadership organizations issued a consensus s...and protection of the Medicare Hospice Benefit. Th...unified message about end-of-life care are the Ame...ne, Hospice and Palliative Nurses Association, Nat...
(Date:1/8/2009)...day, January 9 , , WASHINGTON, Jan. 8 /PRNewsw...national Union (SEIU) President Andy Stern convene...utive Board to discuss the forced transfer of 65,0...nited Healthcare Workers-West (UHW), its third lar...il tomorrow. , , According to reports, several ...
Breaking Medicine News(10 mins):Health News:Be Free From Exam Nerves 2Health News:Antibiotics as Loss Leaders? 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2
... insulin gene to diabetes patients using nanoparti...ing of the American Society of Gene Therapy (ASGT)...d by autoimmune destruction of the insulin produci...f the loss of insulin, blood sugar levels rise too...
...00 patients with culture-positive tuberculosis (TB...igher in HIV-infected patients compared to HIV-uni...en. Furthermore, TB relapse rates were higher in H... standard 6-month therapy when compared to those r...
... one should pop the pill just before sex. The anxi...ews for those suffering from erectile dysfunction ...r longer than the pills. Human and animal trials ...redible alternative to the current treatments avai...
... have enabled better diagnosis and treatment for w...sented at the world's premier conference on cancer... treating many cancers unique to women," Julie Gra... at the University of Washington, said on Sunday. ...
Other Medicine News:Health News:Novel Delivery Method of Insulin Gene to Combat Juvenile Diabetes Developed 2Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2Health News:Gene Therapy a Better Alternative to Viagra Please 2Health News:Advanced Scientific Brings Help for Breast Cancer Survivors 2
(Date:1/7/2009)... ImQuest Life Sciences announced today the success...nd Drug Administration to initiate human clinical ...r IQP-0410. ImQuest anticipates initiating their P...410 is a novel small molecule inhibitor of HIV whi...criptase inhibitor (NNRTI). The compound possesses...
(Date:1/6/2009)...from prior U.S., U.K. and China Trials , , SAN .... (VTI), a development stage company targeting liv... begun for a randomized, controlled, multi-center,...orporeal Liver Assist Device (ELAD) as a treatment... three protocols. The study is open for enrollment...
(Date:1/6/2009)...ewswire/ -- Sequella, Inc., a clinical-stage bioph...ic potential, announced today that SQ109, its lead...(TB), was the first drug approved for evaluation i...port Vaccine Company LLC and Quintiles Transnation...e of Allergy and Infectious Diseases (NIAID), Nati...
(Date:1/5/2009)...ne Pharmaceuticals announced today that it has ini...otein kinase inhibitor, CX-4945, in patients with ...tiple myeloma. The primary endpoints of the oral d...tolerance and PK properties of CX-4945 and to sele...dition, multiple mechanism-related pharmacodynamic...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 1PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 4China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 1China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 2China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 3China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 4China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 5China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 6China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 7China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 8China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 9China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 10China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 11Sentillion Appoints New UK Sales Manager 30669 1Sentillion Appoints New UK Sales Manager 30669 2Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 1Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 2Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 3Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 4
...gress of European Hematology,Association (EHA) -, ...ll/ --,Immunomedics, Inc. , a biopharmaceutical co...to treat cancer and other serious,diseases, today ...,of EHA in Vienna, Austria, showed positive respon...treated with a new,radioimmunotherapy (RAIT) using...
...--Jun 11, 2007 - Geron,Corporation (Nasdaq:GERN) t...s indicating that GRNOPC1, the company,s human,emb...treatment of,spinal cord injury, evades a direct a...ron scientist Ross Okamura at the Federation of,Cl...the findings,could mean that patients treated with...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available.
...catheter incorporates six electrodes which are spa...atheter. Positioned in the Right Atrium, the cathe...ograms. The catheter may then be repositioned to t... ventricular pacing and recording. If indicated, t...
... is the source for a complete line of diagnostic c...ll with the quality, reliability and precise perfo...theter technology. All of our coronary sinus cathe...help minimize the frustration and excess procedure...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures.
Medicine Products: